# A Study in Relapse Prevention of Treatment-Resistant Depression

> **NCT00958568** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 892 (actual)

## Conditions studied

- Treatment Resistant Depression

## Interventions

- **DRUG:** Olanzapine and Fluoxetine combination (OFC)
- **DRUG:** Fluoxetine

## Key facts

- **NCT ID:** NCT00958568
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2012-03
- **Final completion:** 2012-03
- **Target enrollment:** 892 (ACTUAL)
- **Last updated:** 2014-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00958568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00958568, "A Study in Relapse Prevention of Treatment-Resistant Depression". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00958568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*